Literature DB >> 17172389

In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum.

Andrea Kreidenweiss1, Peter G Kremsner, Klaus Dietz, Benjamin Mordmüller.   

Abstract

Nowadays, chloroquine-resistant malaria appears in almost all endemic regions. Ferroquine is a derivative of chloroquine and shows good activity in vitro and in animal models, but the development of cross-resistance is of concern. We tested in vitro susceptibilities of Plasmodium falciparum field isolates from Gabon to ferroquine, chloroquine, and artesunate. As expected, chloroquine resistance was present in all parasite isolates (median 50% inhibitory concentration = 113 nmol/L). Ferroquine (1.94 nmol/L) and artesunate (0.96 nmol/L) were highly active, and no significant correlation between any of the three drugs was observed. In contrast to our findings, previous studies showed an association between chloroquine and ferroquine activities. We could reproduce this association by using different initial parasitemias, but analysis of covariance revealed that initial parasitemia and not parasite strain was the critical determinant for the correlation between chloroquine and ferroquine activities. We conclude that ferroquine is highly active in chloroquine-resistant parasites, and we anticipate no enhanced selection for resistance against ferroquine in chloroquine-resistant parasites.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172389

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  Inhibitory activity of ferroquine, versus chloroquine, against western Kenya Plasmodium falciparum field isolates determined by a SYBR Green I in vitro assay.

Authors:  Fredrick L Eyase; Hoseah M Akala; Jacob D Johnson; Douglas S Walsh
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

2.  Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Enny Kenangalem; Kim A Piera; Barbara Machunter; Emiliana Tjitra; Nicholas M Anstey; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

3.  Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.

Authors:  Christian Supan; Ghyslain Mombo-Ngoma; Matthias P Dal-Bianco; Carmen L Ospina Salazar; Saadou Issifou; Florent Mazuir; Aziz Filali-Ansary; Christophe Biot; Daniel Ter-Minassian; Michael Ramharter; Peter G Kremsner; Bertrand Lell
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

4.  New medicines for malaria.

Authors:  Benjamin Mordmüller
Journal:  Wien Klin Wochenschr       Date:  2010-03       Impact factor: 1.704

5.  Plasmodium vivax susceptibility to ferroquine.

Authors:  M L Leimanis; A Jaidee; K Sriprawat; S Kaewpongsri; R Suwanarusk; M Barends; A P Phyo; B Russell; L Renia; F Nosten
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

6.  Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria.

Authors:  Christian Supan; Ghyslain Mombo-Ngoma; Maryvonne Kombila; Carmen L Ospina Salazar; Jana Held; Bertrand Lell; Cathy Cantalloube; Elhadj Djeriou; Bernhards Ogutu; John Waitumbi; Nekoye Otsula; Duncan Apollo; Mark E Polhemus; Peter G Kremsner; Douglas S Walsh
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

7.  In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum.

Authors:  Maud Henry; Sébastien Briolant; Albin Fontaine; Joel Mosnier; Eric Baret; Rémy Amalvict; Thierry Fusaï; Laurent Fraisse; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

8.  Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Grennady Wirjanata; Boni Sebayang; Kim A Piera; Sergio Wittlin; Richard K Haynes; Jörg J Möhrle; Nicholas M Anstey; Enny Kenangalem; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

Review 9.  The antimalarial ferroquine: from bench to clinic.

Authors:  C Biot; F Nosten; L Fraisse; D Ter-Minassian; J Khalife; D Dive
Journal:  Parasite       Date:  2011-08       Impact factor: 3.000

10.  In-vitro characterization of novel and functional regulatory SNPs in the promoter region of IL2 and IL2R alpha in a Gabonese population.

Authors:  Xiangsheng Huang; Vera Kühne; Jürgen F J Kun; Peter T Soboslay; Bertrand Lell; Velavan Tp
Journal:  BMC Med Genet       Date:  2012-12-07       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.